In recent years, ABBISKO-B (02256) has made significant strides in "source innovation," leveraging its robust drug development capabilities, global clinical expertise, high-quality management systems, and deepening international collaborations. The company has strengthened its leadership in small-molecule platforms and pipelines, establishing a full-cycle portfolio from preclinical to registration-stage clinical assets, including multiple potential best-in-class (BIC) and first-in-class (FIC) candidates. Currently, ABBISKO-B has 22 investigational drugs, with over 10 in clinical development.

These achievements were showcased at the company’s 2025 R&D Day event on October 30. Themed "Collaborating for Innovation, Creating the Future," the event brought together representatives from domestic and international investment firms, clinical experts, and media to discuss ABBISKO-B’s R&D strategy and clinical progress. Key executives, including Founder & CEO Yao-Chang Hsu, Chief Medical Officer Jing Ji, Co-Founder & Chief Scientific Officer Hong-Ping Yu, and senior directors, provided updates on core assets such as pimicotinib (ABSK-021) and highlighted promising candidates like the FGFR4 inhibitor ABSK-011 (epargitinib), ABSK-43, and ABSK-61. The event underscored ABBISKO-B’s dual "depth + breadth" strategy and its commitment to global innovation-driven growth.

**Unlocking the Potential of a "Billion-Dollar Molecule"** CEO Yao-Chang Hsu emphasized ABBISKO-B’s focus on differentiated therapies for unmet medical needs in oncology and beyond, with R&D as the core driver of sustainable growth. The company’s flagship asset, pimicotinib, exemplifies this vision. As the first China-developed CSF-1R inhibitor to enter global Phase III trials for tenosynovial giant cell tumor (TGCT), pimicotinib has received breakthrough therapy designations in the U.S., EU, and China. Its BIC potential extends to other indications like chronic graft-versus-host disease (cGVHD).

In 2023, ABBISKO-B secured a high-value partnership with Merck, including an $85 million milestone payment in April 2024, bringing total upfront and milestone payments to over $150 million. Merck recently highlighted pimicotinib as a key asset for its growth strategy, targeting a 2026 global launch. Analysts project peak global sales exceeding $2 billion, supported by robust Phase III data presented at ESMO 2025, which confirmed durable efficacy and safety in TGCT. With NDA submissions underway in China and the U.S., pimicotinib is poised to redefine TGCT treatment standards.

**Expanding FIC/BIC Portfolios Across Therapeutic Areas** ABBISKO-B’s pipeline spans precision targeting, immunotherapy, and synthetic lethality, with a focus on FGFR and KRAS targets. The FGFR4 inhibitor ABSK-011, another potential "billion-dollar molecule," has shown a 46.7% ORR in advanced HCC patients with FGF19 overexpression (ABSK-011-101 trial) and synergistic efficacy with atezolizumab (ORR >50%, mPFS >7 months in ABSK-011-201). Its breakthrough therapy designation in China positions it as a potential first-in-class precision HCC therapy.

Early-stage assets like the oral PD-L1 inhibitor ABSK-043 (with antibody-like efficacy and combo potential) and the FGFR2/3 inhibitor ABSK-061 (in Phase II for gastric cancer) further diversify the pipeline. PRMT5 inhibitor ABSK-131 and other BIC candidates underscore ABBISKO-B’s innovation depth.

**Financial Strength and Market Confidence** With over RMB 2 billion in cash and a track record of shareholder-friendly buybacks, ABBISKO-B has garnered "Buy" ratings from brokers like Guoyuan International, which set a HK$22.06 target (50% upside), citing pimicotinib’s ESMO data and ABSK-011’s HCC potential. As milestones accelerate, ABBISKO-B’s multi-category, full-cycle pipeline promises sustained value creation.